Image Guided Intensity Modulated Reirradiation (IG-IMRT) With Cetuximab for Locoregionally Confined Recurrent Head and Neck Squamous Cell Carcinoma

Squamous Cell Cancer of the Head and Neck Clinical Trial

Official title: Image Guided Intensity Modulated Reirradiation With Concurrent Cetuximab in the Treatment of Locoregionally Confined Relapsed Squamous Cell Carcinoma of the Head and Neck

Status Withdrawn

Clinical Trial Summary

The standard treatment for head and neck cancer relapses in previously irradiated patients is controversial. Reirradiation has had some success, but many patients still die from their disease. Cetuximab is helpful in relapsed head and neck cancer, and it improves the effectiveness of radiation in some head and neck cancer patients. But, it has not been studied with reirradiation. The purpose of this study is to see the effects, both good and bad, of reirradiation with cetuximab.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Squamous Cell
• Head and Neck Neoplasms
• Neoplasms, Squamous Cell
• Squamous Cell Cancer of the Head and Neck

• NCT number: NCT00934518
• Study type: Interventional
• Source: Milton S. Hershey Medical Center
• Status: Withdrawn
• Phase: Phase 2
• Start date: July 2009
• Completion date: July 2011